Update on angiogenesis;Actualites sur l'angiogenese

Bulletin du Cancer

Volumn 86, Issue 1, 1999, Pages 29-36

  Vandenbunder, Bernard ^a  

^a INSTITUT DE BIOLOGIE DE LILLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR 2; VASCULOTROPIN; ENDOTHELIAL CELL GROWTH FACTOR; LYMPHOKINE; VASCULOTROPIN A;

ANGIOGENESIS; CARCINOGENESIS; CELL INTERACTION; EXTRACELLULAR MATRIX; GENE EXPRESSION; ONCOGENE; PERICYTE; REVIEW; TUMOR VASCULARIZATION; VASCULAR ENDOTHELIUM; ANIMAL; ARTICLE; CHEMISTRY; HUMAN; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PHYSIOLOGY; RAT; VASCULARIZATION;

ANIMALS; ENDOTHELIAL GROWTH FACTORS; ENDOTHELIUM, VASCULAR; EXTRACELLULAR MATRIX; HUMANS; LYMPHOKINES; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; RATS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0032610863     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Algire GH, Chalkley HW, Legallais FY, Park HD. Vascular reactions of normal and maligant tissues in vivo. I. Vascular reactions of mice to wounds and to normal and neoplastic transplants. J Natl Cancer Inst 1945 ; 6 : 73-85.
2. Boshoff C, Endo Y, Collins PD, Takeuchi Y, Reeves JD, Schweickart VL, et al. Angiogenic and HIV-inhibitory functions of KSHV-encoded chemokines [see comments]. Science 1997 ; 278 : 290-4.
3. Sierra-Honigmann MR, Nath AK, Murakami C, Garcia CG, Papapettopoulos A, Sessa WC, et al. Biological action of leptin as an angiogenic factor. Science 1998 ; 281 : 1683-6.
4. Ferrara N, Houck KA, Jakeman IB, Winer J, Leung DW. The vascular endothelial growth Factor family of polypeptides. J Cell Biochem 1991 ; 47 : 211-8.
5. Soker S, Takashima S, Miao HQ, Neufeld G, Klagsbrun M. Neuropilin-I is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 1998 ; 92 : 735-45.
6. Dono R, Texido G, Dussel R, Ehme H, Zeller R. Impaired cerebral cortex development and blood pressure regulation in FGF-2-deficient mice. EMBO J 1998 ; 17 : 4213-25.
7. Zhou M, Sutliff RL, Paul RJ, Lorenz JN, Hoying JB, Haudenschild CC, et al. Fibroblast growth factor 2 control of vascular tone. Nature Med 1998 ; 4 : 201-7.
8. Seghezzi G, Patel S, Ren CJ, Gualandris A, Pintucci G, Robbins ES, et al. Fibroblast growth factor-2 (FGF-2) induces vascular endothelial growth factor (VEGF) expression in the endothelial cells of forming capillaries : an autocrine mechanism contributing to angiogenesis. J Cell Biol 1998 ; 141 : 1659-73.
9. Stan AC, Nemati MN, Pietsch T, Walter GF, Dietz H. In vivo inhibition of angiogenesis and growth of the human U-87 malignant glial tumor by treatment with an antibody against basic fibroblast growth factor. J Neurosurg 1995 ; 82 : 1044-52.
10. Matsuzaki K, Yoshitake Y, Matuo Y, Sasaki H, Nishikawa K. Monoclonal antibodies against heparin-binding growth factor II/basic fibroblast growth factor that block its biological activity : invalidity of the antibodies for tumor angiogenesis. Proc Natl Acad Sci USA1989 ; 86 : 9911-5.
11. Czubayko F, Liaudet CE, Aigner A, Tuveson AT, Berchem GJ, Wellstein A. A secreted FGF-binding protein can serve as the angiogenic switch in human cancer. Nature Med 1997 ; 3 : 1137-40.
12. Bajou K, Noel A, Gerard RD, Masson V, Brunner N, Holst HC, et al. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization, Nature Med 1998 ; 4 : 923-8.
13. Itoh T, Tanioka M, Yoshida H, Yoshioka T, Nishimoto H, Itohara S. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res 1998 ; 58 : 1048-51.
14. Hidai C, Zupancic T, Penta K, Mikhail A, Kawana M, Quertermous EE, et al. Cloning and characterization of developmental endothelial locus-1 : an embryonic endothelial cell protein that binds the alphavbeta3 integrin receptor. Genes Dev 1998 ; 12 : 21-33.
15. Ruegg C, Yilmaz A, Bieler G, Bamat J, Chaubert P, Lejeune FJ. Evidence for the involvement of endothelial cell integrin alphaVbeta3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma. Nature Med 1998 ; 4 : 408-14.
16. Brooks PC, Silletti S, von Schalscha TI, Friedlander M, Cheresh DA. Disruption of angiogenesis by PEX, a noncatalytic metalloproceinase fragment with integrin binding activity. Cell 1998 ; 92 : 391-400.
17. Kyriakides TR, Zhu YH, Smith IT, Bain SD, Yang Z, Lin MT, et al. Mice that lack thrombospondin 2 display connective tissue abnormalities that are associated with disordered collagen fibrillogenesis, an increased vascular density, and a bleeding diathesis. J Cell Biol 1998 ; 140 : 419-30.
18. Witzenbichler B, Maisonpierre PC, Jones P, Yancopoulos GD, Isner JM. Chemotactic properties of angiopoietin-1 and -2, ligands for the endothelialspecific receptor tyrosine kinase Tie2. J Biol Chem 1998 ; 273 : 18514-21.
19. Asahara T, Chen D, Takahashi T, Fujikawa K, Kearney M, Magner M, et al. Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2, modulate VEGF-induced postnatal neovascularization. Circ Res 1998 ; 83 : 233-40.
20. Lin P, Buxton JA, Acheson A, Radziejewski C, Maisonpierre PC, Yancopoulos GD, et al. Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2. Proc Natl Acad Sci USA1998 ; 95 : 8829-34.
21. Hirschi KK, Rohovsky SA, D'Amore PA. PDGF, TGF-beta, and heterotypic cell-cell interactions mediate endothelial cell-induced recruitment of 10T1/2 cells and their differentiation to a smooth muscle fate [published erratum appears in J Cell Biol 1998 Jun 1 ; 141 (5) : 1287]. J Cell Biol 1998 ; 141 : 805-14.
22. Benjamin LE, Hemo I, Keshet E. A plasticity window for blood vessel remodelling is defined by pericyte coverage of cite preformed endothelial network and is regulated by PDGF- B and VEGF. Development 1998 ; 125 : 1591-8.
23. Tachibana K, Hirota S, Iizasa H, Yoshida H, Kawabata K, Kataoka Y, et al. The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract. Nature 1998 ; 393 : 591-4.
24. Wang HU, Chen ZF, Anderson DJ. Molecular distinction and angiogenic interaction between embryonic arteries and veins revealed by ephrin-B2 and its receptor Eph-B4. Cell 1998 ; 93 : 741-53.
25. Rajotte D, Arap W, Hagedorn M, Koivunen E, Pasqualini R, Ruoslahti E. Molecular heterogeneity of the vascular endothelium revealed by in vivo phage display. J Clin Invest 1998 ; 102 : 430-7.
26. Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model [see comments]. Science 1998 ; 279 : 377-80.
27. Hawighorst H, Knapstein PG, Knopp MV, Weikel W, Brix G, Zuna I, et al. Uterine cervical carcinoma : comparison of standard and pharmacokinetic analysis of time-intensity curves for assessment of tumor angiogenesis and patient survival. Cancer Res 1998 ; 58 : 3598-602.
28. Sipkins DA, Cheresh DA, Kazemi MR, Nevin IM, Bednarski MD, Li KC. Detection of tumor angiogenesis in vivo by alphaVbeta3-targeted magnetic resonance imaging. Nature Med 1998 ; 4 : 623-6.
29. Boehm T, Folkman J, Browder T, O'Reilly MS. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997 ; 390 : 404-7.
30. Burrows FJ, Thorpe PE. Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature. Proc Natl Acad Sci USA 1993 ; 90 : 8996-9000.
31. Mauceri HJ, Hanna NN, Beckett MA, Gorski DH, Staba MJ, Stellato KA, et al. Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature 1998 ; 394 : 287-91.
32. Griscelli F, Li H, Bennaceur GA, Soria J, Opolon P, Soria C, et al. Angiostatin gene transfer : inhibition of tumor growth in vivo by blockage of endothelial cell proliferation associated with a mitosis arrest. Proc Natl Acad Sci USA 1998 ; 95 : 6367-72.
33. Sasaki T, Fukai N, Mann K, Gohring W, Olsen BR, Timpl R. Structure, function and tissue forms of the C-terminal globular domain of collagen XVIII containing the angiogenesis inhibitor endostatin. EMBO J 1998 ; 17 : 4249-56.
34. Vaupel P, Schlenger K, Höckel M. Blood flow and tissue oxygenation of human tumors : an update. Adv Exp Med Biol 1992 ; 317 : 139-51.
35. Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW, et al. Hypoxia-mediated selection of cells with disminished apoptotic potential in solid tumours. Nature 1996 ; 379 : 88-91.
36. Carmeliet P, Dor Y, Herbert JM, Fukumura D, Brusselmans K, Dowerchin M, et al. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 1998 ; 394 : 485-90.
37. Ferrara N, Chen H, Davis ST, Gerber HP, Nguyen TN, Peers D, et al. Vascular endothelial growth factor is essential for corpus luteum angiogenesis. Nature Med 1998 ; 4 : 336-40.
38. Hori K, Li HC, Saito S, Sato Y. Increased growth and incidence of lymph node metastases due to the angiogenesis inhibitor AGM-1470. Br J Cancer 1997 ; 75 : 1730-4.
39. Pezzella F, Pastorino U, Tagliabue E, Andreola S, Sozzi G, Gasparini G, et al. Non-small-cell lung carcinoma tumor growth without morphological evidence of neo-angiogenesis. Am J Pathol 1997 ; 151 : 1417-23.